Pipeline

Gylden has a growing pipeline of product candidates that includes synthetic T cell-priming vaccine and immunotherapy candidates for infectious diseases and cancer, and patch-based therapeutic products for migraine/cluster headaches and cardiometabolic disorders. The broadened product pipeline has been supported by the expansion of the Company’s proprietary core technologies.

Core clinical programmes include Dengue, Betacoronavirus, and Pandemic Influenza. First-in-human Phase I clinical trials conducted in Switzerland for Dengue Fever and Betacoronavirus vaccine candidates have been completed with positive results. Our programmes for Pandemic Influenza and other indications are being advanced into clinical trials. Assets acquired via the purchase of Zosano Pharma include therapeutics formulated for patch delivery that have completed later stage clinical trials.